Iomeron (Iomeprol)

Iomeprol contains iodine atoms that absorb X‑ray photons. When injected, the iodine increases the radiodensity of blood and extracellular fluid, creating a contrast difference between enhanced structures and surrounding tissues, which allows detailed imaging of vascular and organ anatomy.

The dose of Iomeron is determined by the prescribing physician based on the specific imaging study, patient weight, renal function, and clinical protocol. Healthcare providers calculate the appropriate volume to achieve optimal contrast enhancement while minimizing risk.

Safety data for Iomeron in pregnancy and lactation are limited. It should be used only when clearly needed and when the potential diagnostic benefit outweighs any possible risk to the fetus or infant. Clinicians should discuss risks with the patient and consider alternative imaging methods when possible.

To order Iomeron, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Iomeron (Iomeprol) is a low‑osmolar, non‑ionic iodinated contrast medium, offering a favorable safety profile compared with high‑osmolar agents that are associated with higher rates of discomfort and renal adverse events. Its iodine concentration provides effective image enhancement while minimizing injection‑related reactions.

Iomeron should be stored below 25 °C in its original packaging, protected from light and moisture. Do not freeze the solution. Before use, inspect the vial for particulate matter or discoloration and ensure the product is at room temperature to avoid injection discomfort.

Iomeron is administered by a trained healthcare professional via intra‑arterial or intravenous injection, typically using a power injector or manual bolus technique. The injection rate and volume are tailored to the imaging protocol and patient characteristics to achieve optimal contrast enhancement.

The most serious risks include severe allergic reactions (anaphylaxis), contrast‑induced nephropathy, and thyroid dysfunction. Patients with known iodine allergy, impaired renal function, or uncontrolled thyroid disease should be evaluated carefully before administration.

Iomeron should be avoided in patients with a documented severe iodine allergy, uncontrolled hyperthyroidism, or acute renal failure unless the diagnostic benefit justifies the risk. Clinicians must assess each patient’s medical history and consider alternative imaging strategies when appropriate.